Achilles Therapeutics plc - American Depositary Shares (ACHL)
1.3850
-0.0050 (-0.36%)
Achilles Therapeutics is a biotechnology company focused on developing innovative cancer therapies that harness the power of the immune system
The company specializes in creating personalized T-cell therapies, which are designed to target and destroy tumor cells by identifying unique neoantigens present in an individual’s cancer. By leveraging advances in genomics and immunotherapy, Achilles aims to improve treatment outcomes for patients with various types of cancer, while minimizing the side effects commonly associated with traditional treatments. Through its research and development efforts, the company is dedicated to transforming the landscape of cancer care.
Achilles Therapeutics (NASDAQACHL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Shares of Achilles Therapeutics plc (NASDAQACHL) are surging following a major strategic announcement from the company. The biotechnology firm revealed plans to discontinue its TIL-based cNeT program and close its ongoing Phase I/IIa clinical trials, CHIRON and THETIS.
U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&P 500 also fell, dropping, 0.28% to 5,197.03.
Shares of STAAR Surgical Company (NASDAQSTAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow traded up 0.49% to 39,319.03 while the NASDAQ rose 1% to 16,4340. The S&P 500 also rose, gaining, 0.75% to 5,250.72.
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
